MannKind Corp. (MNKD)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$4.06+2.53%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · MNKD
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of USD, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | ||||||||||||||||
| Revenues | 393.6 | 349.0 | 285.5 | 199.0 | 99.8 | 75.4 | 65.1 | 63.0 | 27.9 | 11.7 | 174.8 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 |
| Total Revenues | — | — | — | — | — | — | — | — | — | 11.7 | 174.8 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 |
| Cost of Revenues | 40.3 | 26.8 | 17.4 | 20.9 | 16.0 | 16.8 | 15.1 | 20.1 | 19.4 | — | — | — | — | — | — | — |
| Operating Expenses & Income | ||||||||||||||||
| Selling, General & Admin | 199.9 | 144.1 | 94.3 | 94.3 | 91.5 | 77.4 | 59.0 | 74.7 | 79.7 | 75.0 | 46.9 | — | — | — | — | — |
| Operating Income | 9.2 | 38.8 | 72.6 | 8.7 | (64.1) | (47.0) | (47.9) | (44.6) | (76.6) | (108.2) | 67.3 | (344.7) | (179.6) | (169.4) | (147.0) | (140.5) |
| Earnings from Continuing Operations | ||||||||||||||||
| Interest Expense | — | 13.8 | 12.0 | 15.2 | 15.0 | 15.2 | — | — | — | — | — | 24.1 | 20.4 | 21.5 | 21.6 | — |
| Interest & Investment Income | 6.7 | 8.1 | 12.6 | 6.2 | 2.5 | 0.1 | 0.2 | 1.0 | 0.5 | 0.3 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Net Interest Expenses | — | — | — | 9.0 | 12.5 | 15.1 | — | — | — | — | — | 24.1 | 20.4 | 21.5 | 21.6 | — |
| Other Non-Operating Income / Expenses | (57.8) | (37.4) | (42.1) | (19.1) | (23.3) | (33.9) | (9.5) | (7.3) | (10.1) | (9.1) | 58.4 | — | — | — | — | — |
| Asset Writedown | — | — | — | — | — | 0.1 | 1.9 | — | 0.2 | 0.2 | — | 140.6 | — | — | — | — |
| EBT, Incl. Unusual Items | (48.7) | 1.4 | 30.5 | (10.4) | (87.4) | (80.9) | (57.5) | (51.9) | (86.7) | (117.3) | 125.7 | (368.4) | (198.4) | (191.5) | (169.8) | (160.8) |
| Income Tax Expense | (5.0) | (4.5) | 2.9 | 1.6 | 0.0 | 0.0 | (0.2) | 0.0 | 0.2 | 0.1 | 0.0 | 0.0 | (0.4) | (0.4) | (0.4) | — |
| Net Income | ||||||||||||||||
| Net Income | (43.6) | 5.9 | 27.6 | (11.9) | (87.4) | (80.9) | (57.2) | (51.9) | (87.0) | (117.3) | 125.7 | (368.4) | (198.4) | (191.5) | (169.4) | (160.8) |
| Per Share | ||||||||||||||||
| Basic EPS | (0.14) | 0.02 | 0.10 | (0.04) | (0.34) | (0.32) | (0.26) | — | (0.60) | (1.13) | 1.37 | — | — | — | — | — |
| Diluted EPS | (0.14) | 0.02 | 0.10 | (0.04) | (0.34) | (0.32) | (0.26) | — | (0.60) | (1.13) | 1.36 | — | — | — | — | — |
| Revenue per Share | 1.27 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Basic Weighted Avg Shares | 309.2 | 305.6 | 274.4 | 267.0 | 257.1 | 249.2 | 222.6 | — | 144.1 | 104.2 | 92.1 | — | — | — | — | — |
| Diluted Weighted Avg Shares | 309.2 | 314.1 | 283.8 | 267.0 | 257.1 | 249.2 | 222.6 | — | 144.1 | 104.2 | 92.1 | — | — | — | — | — |
| Supplemental | ||||||||||||||||
| EBITDA | — | 51.1 | 80.0 | 13.2 | (60.8) | (45.0) | (45.8) | (43.6) | (73.7) | (104.7) | 71.4 | (331.4) | (161.1) | (155.3) | (132.6) | (124.6) |
| EBIT | 9.2 | 38.8 | 72.6 | 8.7 | (64.1) | (47.0) | (47.9) | (44.6) | (76.6) | (108.2) | 67.3 | (344.7) | (179.6) | (169.4) | (147.0) | (140.5) |
| Effective Tax Rate | 10.4% | — | — | -15.0% | 0.0% | 0.0% | 0.4% | 0.0% | -0.3% | -0.0% | 0.0% | 0.0% | 0.2% | 0.2% | 0.2% | — |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.